| Cimzia (certolizumab pegol) / Astellas, UCB |
SWIFT, NCT01292265: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) |
|
|
| Terminated | 3b | 3 | US | Certolizumab Pegol, Cimzia, CZP | UCB Pharma | Rheumatoid Arthritis | 01/12 | 01/12 | | |
NCT00544154: Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis |
|
|
| Completed | 3 | 247 | Europe | CDP870 | UCB Pharma | Arthritis, Rheumatoid | 01/04 | 01/04 | | |
NCT00548834: Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis |
|
|
| Completed | 3 | 220 | US | CDP870 | UCB Pharma | Rheumatoid Arthritis | 07/04 | 07/04 | | |
NCT00791921: Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA) |
|
|
| Completed | 3 | 230 | Japan | CDP870, Placebo of CDP870 | Otsuka Pharmaceutical Co., Ltd., UCB Japan Co. Ltd. | Rheumatoid Arthritis | 01/10 | 01/10 | | |
|
|
| Completed | 3 | 1648 | Canada, US, Europe | Certolizumab pegol (CZP), Cimzia, Placebo | UCB Pharma | Rheumatoid Arthritis | 03/10 | 03/11 | | |
| Completed | 3 | 194 | Europe | Certolizumab pegol, CDP870, Cimzia, Placebo | UCB Pharma | Rheumatoid Arthritis | 05/10 | 12/10 | | |
|
PICS, NCT01213017: The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients |
|
|
| Completed | 3 | 20 | US | certolizumab pegol, Cimzia | Oklahoma Medical Research Foundation, UCB Pharma | Rheumatoid Arthritis | 01/11 | 04/12 | | |
NCT00160693: Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 402 | US, Europe, RoW | Certolizumab Pegol, Cimzia | UCB Pharma | Rheumatoid Arthritis | 02/11 | 02/11 | | |
Dose Flex II, NCT00753454: Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA) |
|
|
| Completed | 3 | 168 | Canada, US | Certolizumab pegol, Cimzia | UCB Pharma | Rheumatoid Arthritis | 05/11 | 05/11 | | |
NCT00993317: A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis |
|
|
| Completed | 3 | 127 | RoW | Placebo of CDP870, CDP870 200mg, CIMZIA, Methotrexate | Korea Otsuka Pharmaceutical Co., Ltd. | Rheumatoid Arthritis | 08/11 | 08/11 | | |
NCT01374971: Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia) |
|
|
| Completed | 3 | 12 | US | Certolizumab Pegol (CZP), Brand Name: Cimzia, UCB product: Certolizumab Pegol (CDP870), Pre-filled syringe: NDC50474-710-79, Arthroscopic synovial tissue biopsy | Nathan Wei, MD, FACP, FACR:, University of California, San Diego | Rheumatoid Arthritis | 07/12 | 07/12 | | |
| Completed | 3 | 41 | Europe | Placebo, PBO, Certolizumab Pegol (CZP) 200 mg, Cimzia®, CZP, CDP870, Certolizumab Pegol (CZP) 400 mg | UCB Pharma | Rheumatoid Arthritis | 09/12 | 05/13 | | |
|
|
| Completed | 3 | 131 | Europe | Certolizumab Pegol, Cimzia, CDP870 | UCB Pharma | Rheumatoid Arthritis | 12/12 | 12/12 | | |
NCT00850343: Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients |
|
|
| Completed | 3 | 208 | Japan | Certolizumab pegol, Cimzia, CDP870 | Astellas Pharma Inc, UCB Japan Co. Ltd. | Rheumatoid Arthritis | 05/13 | 05/13 | | |
NCT02586246: Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 |
|
|
| Completed | 3 | 86 | Japan | CDP870 | Astellas Pharma Inc, UCB Japan Co. Ltd. | Active Rheumatoid Arthritis | 05/13 | 05/13 | | |
NCT00851318: Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients |
|
|
| Completed | 3 | 285 | Japan | Certolizumab pegol, CDP870, Cimzia, Methotrexate | Astellas Pharma Inc, UCB Japan Co. Ltd. | Rheumatoid Arthritis | 06/13 | 06/13 | | |
NCT01451203: Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis |
|
|
| Completed | 3 | 319 | Japan | Placebo, CZP, CDP870, certolizumab pegol, Cimzia®, methotrexate (MTX) | Astellas Pharma Inc, UCB Japan Co. Ltd. | Rheumatoid Arthritis | 08/13 | 10/14 | | |
NCT01519791: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 880 | Canada, US, Europe, RoW | Certolizumab Pegol, Cimzia, CZP, Placebo, Methotrexate, MTX | UCB Pharma SA | Rheumatoid Arthritis | 07/14 | 09/15 | | |
|
NCT01521923 / 2011-001729-25: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 359 | Canada, US, Europe, RoW | Certolizumab Pegol + Methotrexate (MTX), Cimzia, CZP, MTX, Placebo + Methotrexate (MTX) | UCB Pharma | Rheumatoid Arthritis | 07/15 | 09/15 | | |
|
RAPID-C, NCT02151851: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis |
|
|
| Completed | 3 | 430 | RoW | Certolizumab Pegol, Cimzia, Methotrexate, Placebo | UCB Pharma SA, Belgium, Parexel | Rheumatoid Arthritis | 06/16 | 06/16 | | |
RAPID-C OLE, NCT02319642: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 |
|
|
| Completed | 3 | 347 | RoW | Certolizumab Pegol, Cimzia | UCB Pharma SA, Parexel | Rheumatoid Arthritis | 12/16 | 12/16 | | |
J-RAPID, NCT00791999: Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA) |
|
|
| Completed | 2/3 | 316 | Japan | CDP870 400mg, CDP870 200mg, CDP870 100mg, Placebo of CDP870 | Otsuka Pharmaceutical Co., Ltd., UCB Japan Co. Ltd. | Rheumatoid Arthritis | 01/10 | 01/11 | | |
|
